← All trials
NCT02152306
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2014
- Primary completion
- Mar 1, 2015
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 143
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Boryung Pharmaceutical CompanyLead sponsor
- Seoul National UniversityStudy chair
- Kangbuk Samsung HospitalCollaborator
- Inje UniversityCollaborator
- Chonnam National UniversityCollaborator
- Yonsei UniversityCollaborator
- Chungnam National UniversityCollaborator
- Korea UniversityCollaborator
- Seoul National UniversityCollaborator
- Jeju National UniversityCollaborator
- Dong-A UniversityCollaborator
- Hanyang UniversityCollaborator
- Gachon UniversityCollaborator
- University of UlsanCollaborator
- Catholic University of KoreaCollaborator
- Dongguk UniversityCollaborator
- Keimyung UniversityCollaborator
- Kyungpook UniversityCollaborator
- Wonju Christian HospitalCollaborator
- Pusan National UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.